2023
Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy
Waldron C, Ito S, Wang D, Viswanathan G, Butt A, Goshua G. Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy. Blood 2023, 142: 2317. DOI: 10.1182/blood-2023-189957.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaSecond-line therapyAutoimmune hemolytic anemiaAdult patientsHemolytic anemiaSecond-line treatmentFirst-line treatmentPrevention of thrombosisDegree of anemiaLaparoscopic surgical techniquesPatient's disease statusQuality-adjusted life expectancyRate of infectionProbabilistic sensitivity analysesNet monetary benefitRituximab cyclesTherapy sequencingComplete remissionPartial remissionPerioperative mortalityPrimary outcomeTherapeutic sequencingLaparoscopic techniquePreferred treatmentRelapse risk
2022
Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria
Tormey C, Siddon A. Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria. 2022, 346-363. DOI: 10.1002/9781119719809.ch31.ChaptersParoxysmal nocturnal hemoglobinuriaAutoimmune hemolytic anemiaHemolytic anemiaNocturnal hemoglobinuriaMainstay of therapyChoice of therapyDegree of anemiaBone marrow dysfunctionTypes of symptomsBlood transfusionCold autoantibodiesMarrow dysfunctionRBC destructionPNH patientsPrimary disorderSevere hemolysisRare typeAnemiaAutoantibodiesSingle disorderMedical issuesUnique entityPatientsTherapyHemoglobinuria
2001
Blood Transfusion in Elderly Patients with Acute Myocardial Infarction
Wu W, Rathore S, Wang Y, Radford M, Krumholz H. Blood Transfusion in Elderly Patients with Acute Myocardial Infarction. New England Journal Of Medicine 2001, 345: 1230-1236. PMID: 11680442, DOI: 10.1056/nejmoa010615.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionBlood transfusionMyocardial infarctionElderly patientsHematocrit valuesMortality rateLower short-term mortality rateMedicare beneficiaries 65 yearsShort-term mortality rateUse of transfusionsCoronary artery diseaseBeneficiaries 65 yearsDegree of anemiaLow hematocrit valuesArtery diseaseRetrospective studySubgroup analysisTransfusionPatientsAdmissionInfarctionMortalityHematocritAdverse effectsAnemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply